Zugo-cel (CTX112)
Overview
An allogeneic, gene-edited anti-CD19 CAR-T cell therapy (zugocaptagene geleucel) being developed for autoimmune diseases such as lupus as well as relapsed/refractory B-cell cancers, using CRISPR editing to make an off-the-shelf product.
Phase 1/2, with RMAT designation. Oncology data show a 90% overall response rate and 70% complete response; early autoimmune data show drug-free remissions in lupus. As of the Q2 2026 update, zugo-cel is running in three parallel Phase 1 autoimmune basket trials - rheumatology (lupus, systemic sclerosis, inflammatory myositis), hematology (immune thrombocytopenic purpura, warm autoimmune hemolytic anemia), and a newly initiated autoimmune-neurologic basket (progressive multiple sclerosis, NMOSD, MOGAD, NMDAR/LGI1 autoimmune encephalitis, and stiff person syndrome) - plus a combination study with Lilly's pirtobrutinib in aggressive B-cell lymphomas. Additional readouts expected in H2 2026, supported by a clinical-supply deal with Eli Lilly.